Influenza Medication Market by Drug Class, Delivery Form, Influenza Type, Distribution Channel, End-User - Global Forecast 2025-2030- Product Image

Sale

Influenza Medication Market by Drug Class, Delivery Form, Influenza Type, Distribution Channel, End-User - Global Forecast 2025-2030

Report
182 Pages
October 2024
Region: Global
360iResearch™
ID: 5888966

UP TO €692EUR$697USD£574GBP OFF until Dec 31^st 2024

The Influenza Medication Market grew from USD 3.44 billion in 2023 to USD 3.60 billion in 2024. It is expected to continue growing at a CAGR of 5.00%, reaching USD 4.84 billion by 2030.

The influenza medication market encompasses the production and distribution of antiviral drugs, vaccines, and treatment options specifically designed to mitigate the effects of influenza viruses on human populations. This market is essential due to the recurrent and seasonal nature of influenza outbreaks, which pose significant public health challenges globally. The primary applications include treatment for active influenza infections, prevention through vaccines, and reducing the spread of the virus during annual flu seasons. End-users range from healthcare providers and hospitals to governmental health agencies and individual consumers, each seeking effective treatment and prevention methods.

Market growth is influenced by factors such as the rising incidence of influenza infections, growing awareness about the benefits of vaccination, and advancements in pharmaceutical research increasing the effectiveness of antiviral therapies. The continual development of new strains of the influenza virus creates ongoing demand for innovative vaccines and treatments, offering potential opportunities for pharmaceutical companies to develop new products. For businesses, investing in research focusing on broad-spectrum antivirals, next-generation vaccines, and improved delivery systems could provide a competitive advantage. Additionally, tapping into emerging markets with low penetration rates for influenza medication can also present growth opportunities.

However, challenges include the high cost of research and development, stringent regulatory requirements, and the unpredictability of virus mutations which can reduce the effectiveness of existing medications. Furthermore, vaccine hesitancy and limited health infrastructure in developing regions might impede market growth. Innovation prospects lie in genetic research for personalized medicine approaches and novel drug delivery mechanisms like microneedle patches, which could make vaccines more accessible and increase compliance rates. The nature of the market is highly dynamic, driven by periodic epidemics and technological advancements, requiring constant vigilance and adaptability for sustained success. By prioritizing these innovation avenues and overcoming regulatory barriers, businesses can notably enhance their position in the influenza medication landscape.

Understanding Market Dynamics in the Influenza Medication Market

The Influenza Medication Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of influenza across the globe
- Government initiatives and awareness programs for influenza management
- Growing inclination towards personalized medicine approaches
Market Restraints
- Associated high cost of novel influenza drug development
Market Opportunities
- Surge in influenza drug approvals from regulatory authorities
- Favorable investments for development of new formulations and delivery methods
Market Challenges
- Adverse health outcomes of influenza medications

Exploring Porter’s Five Forces for the Influenza Medication Market

Porter’s Five Forces framework further strengthens the insights of the Influenza Medication Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Influenza Medication Market

External macro-environmental factors deeply influence the performance of the Influenza Medication Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Influenza Medication Market

The Influenza Medication Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Influenza Medication Market

The Influenza Medication Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Influenza Medication Market

The Influenza Medication Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Influenza Medication Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Cocrystal Pharma, Inc., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Qiagen N.V., Sandoz International GmbH, Sanofi SA, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Influenza Medication Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Baloxavir
- Oseltamivir
- Peramivir
- Zanamivir
Delivery Form
- Inhalers
- Intravenous
- Liquid/Syrup
- Tablets/Capsules
Influenza Type
- Type A
- Type B
- Type C
- Type D
Distribution Channel
- Offline
- Online
End-User
- Ambulatory Surgical Centers
- Homecare Facilities
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of influenza across the globe
5.1.1.2. Government initiatives and awareness programs for influenza management
5.1.1.3. Growing inclination towards personalized medicine approaches
5.1.2. Restraints
5.1.2.1. Associated high cost of novel influenza drug development
5.1.3. Opportunities
5.1.3.1. Surge in influenza drug approvals from regulatory authorities
5.1.3.2. Favorable investments for development of new formulations and delivery methods
5.1.4. Challenges
5.1.4.1. Adverse health outcomes of influenza medications
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Influenza Medication Market, by Drug Class

6.1. Introduction
6.2. Baloxavir
6.3. Oseltamivir
6.4. Peramivir
6.5. Zanamivir

7. Influenza Medication Market, by Delivery Form

7.1. Introduction
7.2. Inhalers
7.3. Intravenous
7.4. Liquid/Syrup
7.5. Tablets/Capsules

8. Influenza Medication Market, by Influenza Type

8.1. Introduction
8.2. Type A
8.3. Type B
8.4. Type C
8.5. Type D

9. Influenza Medication Market, by Distribution Channel

9.1. Introduction
9.2. Offline
9.3. Online

10. Influenza Medication Market, by End-User

10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Homecare Facilities
10.4. Hospitals & Clinics

11. Americas Influenza Medication Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Influenza Medication Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Influenza Medication Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. INFLUENZA MEDICATION MARKET RESEARCH PROCESS
FIGURE 2. INFLUENZA MEDICATION MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2030 (%)
FIGURE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. INFLUENZA MEDICATION MARKET DYNAMICS
TABLE 7. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY LIQUID/SYRUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE A, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE B, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE C, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY TYPE D, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 47. CANADA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 48. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. CANADA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 52. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 74. CHINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 75. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 79. INDIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 80. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. INDIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 89. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 90. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 119. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 120. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 135. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 136. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 140. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 141. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 145. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 146. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 150. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 151. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 155. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 165. ITALY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 166. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. ITALY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 180. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 181. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 185. POLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 186. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. POLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 190. QATAR INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 191. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 210. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 225. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
TABLE 239. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Influenza Medication Market, which are profiled in this report, include:

Abbott Laboratories
Agilent Technologies, Inc.
AstraZeneca PLC
Bio-Rad Laboratories, Inc.
Bristol-Myers Squibb Company
Cocrystal Pharma, Inc.
CSL Limited
Daiichi Sankyo Company, Limited
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Lupin Limited
Merck & Co., Inc.
NATCO Pharma Limited
Novartis AG
Pfizer Inc.
Qiagen N.V.
Sandoz International GmbH
Sanofi SA
Shionogi & Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Zydus Pharmaceuticals, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	182
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 3.6 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.84 Billion
Compound Annual Growth Rate	5.0%
Regions Covered	Global
No. of Companies Mentioned	26

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3518EUR$3,545USD£2,919GBP €3909EUR$3,939USD£3,243GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6224EUR$6,272USD£5,164GBP €6915EUR$6,969USD£5,738GBP

Understanding Market Dynamics in the Influenza Medication Market

Exploring Porter’s Five Forces for the Influenza Medication Market

Applying PESTLE Analysis to the Influenza Medication Market

Analyzing Market Share in the Influenza Medication Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Influenza Medication Market

Strategic Recommendations for Success in the Influenza Medication Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Influenza Medication - Global Strategic Business Report

Anti-Viral Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Japan Influenza Medications Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

Influenza Treatment Global Market Report 2024

Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

About the Influenza Drug Market